Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

BioNTech is also exploring combinations with antibody-drug ... inhibitors do, while also neutralizing the immunosuppressive ...

The term “protease inhibitor” refers to a class of medications rather than to a single medication. Specifically, they are antiviral drugs. But unlike the many, more common antiviral drugs that ...

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Adlai Nortye Ltd. Sponsored ADR (ANL – Research Report) and ...

BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.

Duality Biologics Ltd. presented preclinical data on DB-1419, a potentially first-in-class bispecific antibody-drug conjugate (ADC) consisting of a humanized antibody targeting B7-H3 and PD-L1 ...